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AbstrAct
Background Coronary artery disease (CAD) is associated 
with an increased prothrombotic tendency and is also 
linked to unfavourably altered clot microstructure. We have 
previously described a biomarker of clot microstructure 
(d
f) that is unfavourably altered in acute myocardial 
infarction. The df biomarker assesses whether the blood 
will form denser or looser microstructures when it clots. 
In this study we assessed in patients with stable chest 
pain whether d
f can differentiate between obstructed and 
unobstructed CAD.
Methods A blood sample prior to angiography was 
obtained from 251 consecutive patients undergoing 
diagnostic coronary angiography. Patients were 
categorised based on angiographic findings as presence 
or absence of obstructive CAD (stenosis ≥50%). The blood 
sample was assessed using the d
f biomarker, standard 
laboratory markers and platelet aggregometry (Multiplate).
Results A significant difference (p=0.028) in df was 
observed between obstructive CAD (1.748±0.057, 
n=83) and unobstructive CAD (1.732±0.052, n=168), 
where patients with significant CAD produce denser, 
more tightly packed clots. d
f was also raised in men with 
obstructive CAD compared with women (1.745±0.055 
vs 1.723±0.052, p=0.007). Additionally df significantly 
correlated with the platelets response to arachidonic 
acid as measured by the ASPItest area under the 
curve readings from platelet aggregometry (correlation 
coefficient=0.166, p=0.008), a low value of the ASPItest 
indicating effective aspirin use was associated with looser, 
less dense clots.
Conclusions For the first time, we characterise clot 
microstructure, as measured by d
f, in patients with stable 
CAD. df can potentially be used to risk-stratify patients 
with stable CAD and assess the efficacy of therapeutic 
interventions by measuring changes in clot microstructure.
IntroductIon
Coronary artery disease (CAD) is associ-
ated with an underlying systemic imbalance 
in haemostasis caused by the presence of a 
hypercoagulable state and a decrease in fibri-
nolysis.1–4 While CAD has been linked to an 
increased prothrombotic state, no marker 
has been identified that can accurately assess 
abnormalities of global haemostasis due to this 
process and to severity of disease. Identifying 
a global haemostatic marker of coagulability 
and fibrinolysis may be important in strati-
fying risk of atherothrombosis and providing 
the basis for individualised therapeutic 
management.
Previous studies have identified that 
abnormal clot microstructure is of significant 
importance in the pathophysiology of many 
vascular and inflammatory disease states 
including CAD.5–8 However, the standard 
techniques for assessing clot microstructure 
do not translate to being used as routine 
markers in a clinical setting.9 This has led 
to the development of a technique that 
uses assessment of the viscoelastic proper-
ties of coagulating blood to quantify its clot 
microstructure as a fractal dimension, df.
9 In 
contrast to standard coagulation assays, the df 
measurement is performed using unadulter-
ated whole blood in a near patient setting and 
provides rapid assessment of coagulation.9 
Lower values of df correspond to less dense, 
less branched, weaker clots, whereas higher 
df values represent denser, more complex, 
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Basic and translational research
Key questIons
What is already known about this subject?
Coronary artery disease (CAD) alters coagulation and 
is associated with an increased risk of thrombotic 
disease.
What does this study add?
We show how a novel marker of clot microstructure 
can be used to characterise the level of disease in 
stable CAD and therapeutic manipulation.
How might this impact on clinical practice?
We identify a possible tool for risk-stratifying patients 
with stable CAD, alongside the potential to assess the 
efficacy of therapeutic interventions.
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Figure 1 Diagram of a double-gap concentric cylinder 
measurement geometry. The double-gap geometry consists 
of a stationary cup or stator into which a 6.6 mL sample of 
blood is added after which a bob that is free to rotate called 
a rotor is then lowered into the sample. The movement of the 
rotor is controlled by an AR-G2-controlled stress rheometer 
and will oscillate at four different frequencies (0.20, 0.43, 0.93 
and 2.00 Hz) sequentially over time.
stronger clots.9 The df measurement has been previously 
validated in several disease states and has also been used 
to stratify the severity of disease, however, its role in stable 
CAD remains unclear.10–14
The aim of the present study was to characterise clot 
microstructure in CAD. The hypothesis was that for a 
cohort of patients with suspected CAD undergoing diag-
nostic angiography, df will be unfavourably altered in 
those patients with obstructive CAD compared with those 
with no or unobstructive CAD.
Methods
Patient population
This study was conducted in accordance with good clin-
ical practice and has been reviewed and approved by the 
by the local Research Ethics Committee (Wales REC 7). 
We screened all consecutive patients undergoing routine 
diagnostic coronary angiography for evaluation of new 
onset chest pain, who have no previously confirmed 
CAD. Eligible patients were recruited from two hospitals 
in South Wales (a large teaching hospital and a district 
general hospital) from November 2012 to August 2014. 
We excluded patients with active cancer; liver disease; 
chronic kidney disease stage IV and V or on dialysis; <18 
years of age; known clotting disorders; history of myocar-
dial infarction, stroke or thromboembolic disease; severe 
heart failure (ejection fraction <35% or clinically New 
York Heart Association (NYHA) stage III–IV) or taking 
anticoagulants at the time of the study. Written informed 
consent was obtained from all patients before recruit-
ment in the study.
One venous blood sample was collected before angi-
ography. Data including demographics, medical history 
and current medications were collected for each patient, 
including presence of diabetes, family history of CAD 
(history of acute myocardial in a first-degree relative), 
hypercholesterolaemia (total cholesterol >5 mmol/L 
or currently on medication for high cholesterol) and 
smoking history.
Patients were divided in two groups based on coro-
nary angiographic findings: those with angiographically 
normal arteries or minor irregularities but no significant 
stenosis (≥50%) were termed unobstructed, those with 
any coronary stenosis ≥50% being defined as obstructive 
CAD. Clinicians reporting coronary angiography find-
ings were blinded to the results of biomarker analysis and 
the operator performing biomarker analysis was blinded 
to the angiography results.
blood sampling
Each blood sample was divided into several aliquots. 
One aliquot of whole venous blood was immediately 
transferred and used for viscoelastic measurements. The 
remaining aliquots were used to perform standard coag-
ulation screens, full blood count, thrombin generation or 
platelet aggregometry (see below).
Viscoelastic measurements
The viscoelastic measurements are based on attainment 
of the gel point (GP) from which the fractal dimension, 
df, is determined.
9 The GP technique has been previously 
validated for use with blood in several studies.10–15 Briefly, 
blood is placed within the double concentric measuring 
geometry of a controlled stress rheometer, AR-G2 (TA 
Instruments, New Castle, DE, USA) which is held a 
constant temperature of 37°C±0.1°C (figure 1). Immedi-
ately after loading the blood into the AR-G2, viscoelastic 
analysis is preformed using small amplitude oscillatory 
shear measurements at varying frequencies; 2, 0.93, 0.43 
and 0.2 Hz, with an applied peak stress amplitude of 0.03 
Pa. Repeatedly performing these measurements over 
time allows for the measurement of the GP (figure 2). The 
GP marks the transition of the blood from a viscoelastic 
liquid to a viscoelastic solid, where the GP identifies the 
formation of the incipient blood clot or the first point 
which a sample spanning (haemostatic) structure can be 
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Figure 2 Gel point (GP) trace. This represents a typical GP 
result for one sample of blood. The illustration demonstrates 
how phase angle, δ, changes as coagulation progresses. δ 
has a range of 0° to 90°, where 90° identifies a purely viscous 
response and 0° identifies a purely elastic response with 
any value in between being a measure of the viscoelastic 
response to imposed stress. In a material that is changing 
from a liquid to a solid such as blood, there will be a 
decrease in δ. At the establishment of the incipient clot, 
when the clot becomes a viscoelastic solid, there is a point 
where the value of δ will be independent of frequency called 
the GP. The structural property of the incipient clot (in terms 
of its fractal dimension, df) is derived from this frequency 
independent value of δGP.
Basic and translational research
identified.9 In figure 2 the GP is located when the four 
frequencies cross-over. From the GP measurement we can 
quantify how the fibrin clot is organised by calculating its 
corresponding fractal dimension, df.
9
Laboratory markers
A 4 mL aliquot of blood was drawn into tubes containing 
EDTA for Full Blood Count (FBC) analysis and then 
analysed using a Sysmex XE 2100 (Sysmex UK, Milton 
Keynes, UK). Parameters measured included: haemo-
globin, haematocrit and platelet count. A 4.5 mL aliquot 
was collected into tubes containing citrate and then anal-
ysed using a Sysmex CA1500 (Sysmex UK, Milton Keynes, 
UK). Parameters measured included: prothrombin time, 
activated partial thromboplastin time, factor VIII and 
Clauss fibrinogen. D-dimer analysis was carried out using 
a latex immunoturbidimetric assay Hemosil HS D-dimer 
(Instrumentation Laboratory, Warrington, UK) with a 
ACL TOP 500 (Instrumentation Laboratory, Warrington, 
UK). Plasma cytokines (interleukin 6 and myeloperoxi-
dase) were measured and quantified using a standard 
ELISA (Quantikine, R+D Systems, UK), according to the 
manufacturer’s instructions.
thrombin generation
Thrombin generation was measured using the Thrombin 
Generation Assay (TGA, Technoclone Diagnostics, 
Vienna, Austria). Plates were loaded into the fluorogenic 
plate reader TECAN infinite F200 pro (Labtech Interna-
tional, Uckfield, UK) and read every 60 s for 1 hour. TGA 
software was used to calculate individual thrombin gener-
ation curves.
Platelet aggregation measurements
Measurement of platelet aggregation was achieved using 
the Multiplate analyser (Dynabyte GmBH, Munich, 
Germany). An aliquot of whole blood (3 mL) was trans-
ferred to hirudin tubes (Roche Diagnostics GmbH, 
Mannheim, Austria, Ref: 06675751) and kept at room 
temperature for 30 min before testing. Three hundred 
microlitres of whole hirudinated blood was added to 
300 µL of saline preheated to 37°C and allowed to incu-
bate for 3 min in individual test cells. Following incubation 
platelet activation was induced by addition of specific 
agonists to respective test cells, and electrical imped-
ance was recorded. The agonists included ADP (20 µL 
of 0.2 mM stock solution) for measuring P2Y12 receptor 
aggregation, which is inhibited by clopidogrel and other 
thienopyridines. The second agonist was ASPItest reagent 
(20 µL of 15 mM stock solution) for measuring the inhib-
itory effect of aspirin.
statistical analysis
A power calculation was performed assuming a mean 
difference in df of 0.025 (based on pilot data) between 
unobstructive and obstructive CAD. Taking a SD of 
0.045, a power of 0.85 and significance value set at 0.05 a 
minimum of 65 patients in both groups is required. With 
the study designed for consecutive patients and with a 
likely recruitment bias towards unobstructive CAD, we 
aimed to recruit double that number. Descriptive anal-
yses were performed to establish baseline characteristics 
for both groups. Categorical variables are summarised 
using percentages and compared using χ2 tests while 
continuous variables are presented using mean and SD 
unless otherwise stated. Differences between groups were 
compared using two sample t-tests for parametric data 
or Kruskal-Wallis test for non-parametric data. Pearson 
correlation was undertaken to explore associations 
between df and demographic, laboratory markers and 
platelet aggregometry. Statistical analysis was performed 
using Minitab V.15 software (Havertown, Pennsylvania, 
USA) and deemed significant when p<0.05.
resuLts
A total of 275 patients were recruited, full angiographic, 
viscoelastic measurements and platelet aggregation 
measurements were performed successfully in 251. Of 
the 251 patients recruited, 168 patients were classed as 
unobstructed CAD and 83 patients as obstructive CAD. 
The baseline characteristics and patient demographics 
for the two groups is recorded in table 1. Significant 
differences between the demographics of the two groups 
are observed for age (p=0.013), sex (p<0.001) and statin 
use (p=0.045). Results of the viscoelastic testing, labora-
tory markers and platelet aggregometry measurements 
can be found in table 2.
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Table 1 Patient baseline characteristics and demographics
Normal (n=80)
Unobstructed CAD 
(n=88) Unobstructed (n=168) Obstructive CAD (n=83) p Value
Age 58.6±8.8 63.5±10.3 61.1±9.8 64.3±9.7 0.013
Sex (M:W) 32:48 (40%) 45:43 (51%) 77:91 (46%) 58:25 (70%) <0.001
BMI 30.3±5.4 30.8±5.7 30.4±5.5 30.0±7.0 0.59
Smoking (current) 10 (12%) 14 (16%) 24 (14%) 14 (17%) 0.34
Hypercholesterol 54 (68%) 71 (81%) 125 (74%) 69 (83%) 0.31
HTN 40 (50%) 40 (45%) 90 (54%) 43 (52%) 0.82
DM 12 (15%) 29 (33%) 41 (24%) 16 (19%) 0.19
FHx MI 33 (42%) 47 (53%) 80 (48%) 39 (47%) 0.91
Antiplatelet use 60 (75%) 51 (58%) 111 (66%) 66 (78%) 0.11
  Aspirin 58 34 92 57
  P2Y12 0 6 6 2
  Both 2 11 13 7
Statins 50 (63%) 50 (63%) 109 (65%) 66 (80%) 0.045
All Caucasians but two. Other lowering lipid drugs: four ezetimibe and two fenofibrates.
BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; FHx MI, family history of stroke myocardial infarction; HTN, 
hypertension; M:W, men:women.
Table 2 Results of the viscoelastic testing, standard and specific markers for non-severe and severe CAD groups
Normal (n=80)
Unobstructed CAD 
(n=88) Unobstructed (n=168) Obstructive CAD (n=83) p Value
df 1.728±0.052 1.735±0.053 1.732±0.052 1.749±0.057 0.028
IL-6 50.1±5.0 52.1±4.3 51.6±4.1 67.6±7.5 0.38
MPO 4541±1450 4563±1471 4544±1456 4636±1482 0.66
CRP 3.6±3.2 3.7±3.0 3.7±2.8 3.7±3.0 0.75
Hb (g/dL) 14.0±1.2 14.3±1.3 14.1±1.3 14.2±1.2 0.45
Plt (×109/L) 263±67 253±69 258±67 249±53 0.22
HCT (g/g) 0.418±0.033 0.425±0.035 0.422±0.035 0.437±0.035 0.24
PT (s) 10.5±0.4 10.5±0.5 10.5±0.4 10.6±0.5 0.057
APTT (s) 25.8±2.1 25.8±1.9 25.8±2.0 26.2±1.9 0.13
FBG (g/L) 3.3±0.6 3.4±0.7 3.3±0.6 3.4±0.7 0.26
DD* 94 (IQR 71–147) 122 (IQR 81–178) 110 (IQR 74–167) 131 (IQR 80–209) 0.095
TG 137±44 119±50 128±76 136±93 0.51
FVIII 132±44 138±46 135±45 135±38 0.99
Multiplate ADP 85.3±32.2 77.1±27.5 81.4±29.8 76.9±28.5 0.24
Multiplate ASPI* 28 (IQR 13–70) 30 (IQR 18–83) 29.0 (IQR 15.8–78.1) 25.4 (IQR 18.0–64.5) 0.41
*Median and interquartile values reported.
APPT, activated partial thromboplastin time; CAD, coronary artery disease; CRP, C-reactive protein; DD, D-Dimer; FBG, fibrinogen; FVIII, 
Ffactor VIII; Hb, haemoglobin; HCT, haematocrit; IL-6, interleukin 6; MPO, myeloperoxidase; Plt, platelet count; PT, prothrombin time; TG, 
thrombin generation.
Viscoelastic measurements
A significant increase in the value of df was observed for 
those patients with obstructive CAD when compared 
with unobstructed (df=1.748±0.057 vs 1.732±0.052, 
p=0.028). We also preformed an analysis of covariance 
and analysis using a general linear model. This analysis 
demonstrated the difference in df between obstructive 
CAD and the unobstructed group remains significant 
(p<0.05) even when we adjust for fibrinogen concentra-
tion, haematocrit, antiplatelet function or the presence 
of hypercholesterolaemia. Furthermore, we analysed the 
data by dividing the unobstructed group into two separate 
groups, normal (n=80) and unobstructed CAD (n=88) 
giving total of three groups. Using a one-way analysis 
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Figure 3 A graph showing the dispersion of df 
measurements among the unobstructed and the obstructed 
coronary artery disease (CAD) groups, where a significant 
increase in the value of df was observed for those patients 
with obstructive CAD when compared with unobstructed 
(df=1.748±0.057 vs 1.732±0.052, p=0.028).
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of variance (ANOVA; 95% CI) we observe a non-signifi-
cant (p=0.053) increase in df when comparing the three 
groups: normal (n=80, df=1.728±0.052); unobstructed 
CAD (1%<stenosis<50%) (n=88, df=1.735±0.053) and 
obstructed CAD (≥50% stenosis) (n=83, df=1.748±0.057). 
In addition, we reviewed the obstructed CAD group and 
classified it into 1, 2 and 3 vessel disease to assess whether 
there was a difference in df. We found no significant 
difference in df depending on number of diseased vessels 
(p=0.83) (1 vessel (n=40) df=1.738±0.060, 2 vessel (n=27) 
df=1.770±0.055 and 3 vessel (n=14) df=1.752±0.056). 
Dispersion of df for both the unobstructed and obstructed 
CAD groups can be seen in figure 3.
Comparing the df against patient demographics, we 
only found significant differences in men versus women, 
where df was raised in men (1.745±0.055 vs 1.723±0.052, 
p=0.007), and in smokers versus non/ex-smokers, where 
df was raised in smokers (1.761±0.037 vs 1.733±0.055, 
p=0.001). The differences observed in smokers versus 
non/ex-smokers persisted when studying the obstructive 
(1.754±0.050 vs 1.728±0.054, p=0.003) and unobstructive 
CAD (1.776±0.042 vs 1.745±0.059, p=0.043) groups.
Laboratory markers and thrombin generation
We found no significant difference between unob-
structed and obstructive CAD for any of the standard 
laboratory tests (see table 2). Positive correlations were 
observed between df and two of the laboratory markers: 
haematocrit (correlation coefficient=0.458, p=0.001) and 
fibrinogen concentration (correlation coefficient=0.242, 
p=0.001), where these relationships persisted when 
studying all patients recruited or in their individual 
obstructive (fibrinogen concentration: 0.308, p=0.004; 
haematocrit: 0.412, p=0.001) or unobstructive (fibrin-
ogen concentration: 0.186, p=0.016; haematocrit: 0.477, 
p=0.001) CAD groups. We also reanalysed the laboratory 
markers data using one-way ANOVA (95% CI) to look at 
the data in three groups, namely normal, unobstructed 
CAD and obstructed CAD, however, we found no differ-
ences between the three groups.
Platelet aggregometry
The use of antiplatelet therapy was only recorded when 
it was known to be effective in the patient. The effec-
tiveness of antiplatelet therapy was determined from 
platelet aggregometry measurements taken at the 
same time as df measurements. Effective aspirin use is 
recorded by an ASPI reading of below 40IUs as deemed 
in a previous publication.16 Effective inhibition of P2Y12 
receptor on the platelet is determined by an ADP value 
of below 47IUs.17 We found that 70% of patients were 
receiving some form of antiplatelet therapy with 89% of 
those receiving monotherapy and 11% dual antiplatelet 
therapy. Of the monotherapy group 95% were taking 
aspirin and 5% were taking a P2Y12 inhibitor. A signif-
icant positive correlation was observed between ASPI 
and df (0.157 p=0.014) but not ADP (0.089 p=0.34). We 
found a non-significant increase in df for those not taking 
antiplatelet therapy compared with those taking anti-
platelet therapy (1.735±0.053 vs 1.746±0.053, p=0.12). 
A significant reduction in df was observed for patients 
on dual antiplatelet therapy compared with no therapy 
(1.722±0.053 vs 1.746±0.053, p=0.048).
dIscussIon
This study for the first time shows that a whole blood 
biomarker that quantifies clot microstructure can be used 
to discriminate between those with unobstructed and 
those with obstructive CAD. We show that patients with 
obstructive CAD produce clots with a significantly higher 
df (1.748±0.057) when compared with those patients 
without obstructive CAD (1. 732±0.052) (p=0.028) (see 
figure 3). An increased value of df can be illustrated using 
a previously published computational model of a simpli-
fied branching network, which shows the relationship 
between df and the mass of the network.
18 19 In figure 4 we 
show that a change in df from 1.732 (unobstructed CAD) 
to 1.748 (obstructive CAD) would correspond to an addi-
tional 25% more mass that would need to be incorporated 
into the structure of the incipient clot. Consequently, 
patients with obstructive CAD are more likely to produce 
clot microstructures that are consistently denser and 
more tightly packed, resulting in a clot that is of poorer 
quality, harder to breakdown and more likely to form a 
thrombus. This may be linked to the underlying hyper-
coagulable state of CAD patients suggested in previous 
studies.1 2 20
While a difference in the value of df is observed 
between the obstructive and unobstructive CAD groups, 
it is important to note that several patient demographics 
are also significantly different (see table 1). We found 
age was significantly different, where patients with unob-
structed CAD were on average 3.2 years younger than the 
obstructive CAD group (61.1+9.8 years vs 64.3+9.7 years, 
respectively, p=0.013). This is perhaps unsurprising as 
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Figure 4 Fractal dimension (df) versus mass. Graph 
showing the simplified non-linear relationship between df 
and the amount of mass incorporated into the incipient 
clot microstructure. Fibrin networks have fractal properties, 
where the mass, M, is related to df by the following power 
law equation (M≈ɛdf, where ɛ is some length scale value in 
the range 100 nm to 10 µm). The mass value on the y-axis 
is normalised to the unobstructed CAD value of df=1.732, 
where at a df of 1.732 the normalised mass value is equal 
to 1 (blue dotted lines). The figure illustrates that a structure 
that forms with a df of 1.748, like the mean value of the 
obstructive CAD group (red dotted lines) would have an 
increased relative mass compared with a structure that 
formed with a df value of 1.732, having 1.27 times more 
mass.
age is a primary risk factor in advanced CAD.21 However, 
we found no significant correlations between age and 
df either in all patients or in their individual groups (all 
patients: correlation coefficient=−0.118, p=0.064; obstruc-
tive CAD: −0.210, p=0.055; unobstructive CAD: −0.105, 
p=0.164). Furthermore, in a previous study with a healthy 
control (70.6±7.1 years), there was no correlation between 
age and df.
11 The findings herein may be surprising 
considering studies have shown that increased age is 
often associated with an increase in certain haematolog-
ical characteristics, such as fibrinogen concentration.22 
Fibrinogen concentration has also been associated with 
cardiovascular risk; in the present study we did identify 
a positive correlation between df and fibrinogen concen-
tration but fibrinogen was not significantly raised when 
comparing obstructive and unobstructive CAD.23 This 
suggests that while age is associated with advanced CAD, 
age itself is not the driving force behind the development 
of abnormal clot formation.
Sex was also significantly different between obstructive 
and unobstructive CAD, where there was a significantly 
higher proportion of men in the obstructive CAD group 
compared with unobstructed CAD group (70% vs 46%, 
p<0.001). This is unsurprising as CAD is often reported 
as more prevalent in men.21 When comparing dfversus 
sex, we found that df was significantly increased in men 
compared with women (1.746+0.055 vs 1.727+0.052, 
p=0.007). In the present study, the higher value of df 
in men may be due to the increased number of men 
with obstructive CAD compared with women, however, 
the raised df in men persists across both the obstructed 
(1.753±0.059 vs 1.737±0.053) and unobstructed 
(1.740±0.059 vs 1.725±0.053) CAD. Another rationale 
may be that men in general have an underlying propen-
sity to form denser and more compact clots (hence 
higher dfs) than women. However, a previous study 
which used a healthy control (n=74) did not find a differ-
ence in the value of df between men and women.
11 A 
previous study investigating myocardial infarction with df 
found that men were also more likely to have increased 
df values compared with women.
14 Men with CAD have 
been shown to have a higher prevalence of experiencing 
an acute coronary syndrome or fatal coronary heart 
disease.21 A final explanation may be that men with CAD 
(either obstructive or unobstructive) are more likely to 
form denser more compact clots (hence higher dfs) than 
women, thus are at an increased risk of suffering an acute 
coronary syndrome.
Statin use was also found to be different when 
comparing the obstructive and unobstructive CAD 
groups. Statin use was significantly increased in the 
obstructive CAD group (80% vs 65%, p=0.045) (table 2). 
With the increased mean age and percentage of men 
in the obstructive CAD group, it is unsurprising that 
statin use is raised with both being strong indicators for 
statin use.24 25 A previous study has shown that statin use 
has a mediating effect on clot microstructure forma-
tion producing clots that are more open and porous 
compared with those formed in its absence.26 As a result, 
we would expect the group with the highest percentage 
of statin use to have the lowest value of df, however, that 
is not the case. In the present study, the obstructive CAD 
group has around 80% (compared with 65% in the unob-
structive CAD group) of patients taking statin while also 
having the highest value of df. When comparing statin use 
and df for all patients recruited into the study, we found 
no significant difference between those taking and those 
not taking statins (1.736+0.055 vs 1.741+0.049, p=0.54). A 
possible reason being the wide range of different types of 
statin being used in the patients in this study, which may 
have differing effects alongside the varying comorbidities 
and heterogeneous nature of the patient population.
A significant increase in df was also observed in smokers 
compared with non-smokers/ex-smokers (1.761±0.037 vs 
1.733±0.055, p=0.001). While the number of smokers and 
non/ex-smokers was not significantly different between 
the obstructive and unobstructive CAD groups, smoking 
has been suggested to contribute to the formation of 
hypercoagulable conditions which could account for its 
relationship with df.
27
In this study, we found that antiplatelet use was not 
significantly different between the obstructive and unob-
structive CAD groups (78% vs 66%, p=0.11). We found 
group.bmj.com on December 13, 2017 - Published by http://openheart.bmj.com/Downloaded from 
7Sabra A, et al. Open Heart 2017;4:e000562. doi:10.1136/openhrt-2016-000562
Basic and translational research
that when comparing effective antiplatelet (either mono 
or dual) therapy against non-effective/no antiplatelet 
therapy, with respect to df, patients with effective anti-
platelet therapy had a non-significant decrease in the 
value of df (1.735±0.053 vs 1.746±0.053, p=0.11). We 
have previously shown that mono-antiplatelet therapy 
with aspirin can lower df in patients with acute vascular 
disease, however, this was in a dose of 300 mg of aspirin, 
not 75 mg, and the effect was only an acute lowering 
of df which returned to baseline levels after 24 hours.
11 
Despite the fact that monotherapy did not significantly 
reduce the value of df in the present study, we did find a 
significant positive correlation (0.157, p=0.014) between 
df and the ASPI test (Multiplate) results showing that the 
stronger the inhibition of the aspirin the lower the value 
of df. Of those patients receiving antiplatelet therapy, 12% 
were receiving dual antiplatelet. We found a significantly 
reduced value of df in those receiving dual antiplatelet 
therapy compared with no therapy (1.722±0.053 vs 
1.746±0.053, p=0.048). These results suggest that 
dual antiplatelet therapy is effective in mediating clot 
microstructure, where patients have lower values of df 
corresponding to the production of less densely packed 
and more porous clots.4 This study provides further 
evidence of the potential of df in monitoring the effects of 
antiplatelet therapy on clot microstructure formation.11
The limitations of this study include discrepancy in 
the numbers collected for both groups. As the study 
was designed to collect consecutive patients admitted 
for a routine diagnostic angiography, it was not possible 
to collect matched patients for both groups. This has 
resulted in twice as many patients with non-obstruc-
tive CAD being recruited (n=168 vs n=83). While this 
reduces the power of any statistical analysis, the numbers 
recruited are still sufficient for meaningful interpretation 
of the results. Finally, the presence of a 50% stenosis on 
invasive coronary angiography was used to define the 
presence of obstructive CAD. This is an accepted gold 
standard with prognostic implications. However, intravas-
cular imaging was not used routinely so it is possible that 
some of the patients with angiographic irregularities or 
lesions <50% may have contained positively remodelled 
plaques with potentially vulnerable morphology. It is not 
clear how the presence of these plaques might effect df 
and requires further study.
In this study, we have performed the first characterisa-
tion of clot microstructure in patients with stable CAD. 
We have shown that in patients investigated for stable 
chest pain, the presence of obstructive CAD is associ-
ated with an increased potential to produce denser more 
compact clots and unfavourable morphology. We have 
also identified that men with obstructive CAD disease 
produce unfavourable clot microstructures compared 
with women. Additionally, patients with CAD receiving 
dual antiplatelet therapy have a reduced df value linked 
to a more favourable looser less compact clot. The df 
measurement can potentially be used to risk-stratify 
patients with stable CAD and has the potential to assess 
the efficacy of therapeutic interventions by measuring 
changes in clot microstructure.
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